Lambda-interferons (IFN-λs) have been demonstrated as having the ability to inhibit HIV replication in macrophages. However, specific differences in signaling transduction and anti-HIV activity in macrophages between different IFN-λs are unclear. Here, we showed that although all 3 members of (IFN-λ1, λ2, and λ3) IFN-λ family induced the expression of a number of genes of janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling pathway in monocyte-derived macrophages, IFN-λ1 or IFN-λ3 induced higher levels of antiviral IFN-stimulated genes (ISGs) expression than did IFN-λ2. In addition, IFN-λ1 or IFN-λ3 induced higher levels of several pattern recognition receptors (PPRs) than did IFN-λ2. Incubation of IFN-λs with HIV-infected macrophages showed that IFN-λ1 or IFN-λ3 is more potent in anti-HIV activity than IFN-λ2. We also showed that IFN-λ treatment before HIV infection was more potent in HIV inhibition than that after HIV infection. Further investigations showed that the inductions of ISGs and PPRs expression by IFN-λs were largely compromised by HIV infection. These findings provide further experimental evidence that IFN-λs have therapeutic potential in treatment of HIV infection.
Get full access to this article
View all access options for this article.
References
1.
AlmeidaGM, de OliveiraDB, MagalhaesCL, BonjardimCA, FerreiraPC, KroonEG. 2008. Antiviral activity of type I interferons and interleukins 29 and 28a (type III interferons) against Apeu virus. Antiviral Res, 80(3):302–308.
2.
AnkN, PaludanSR. 2009. Type III IFNs: new layers of complexity in innate antiviral immunity. Biofactors, 35(1):82–87.
3.
AnkN, WestH, BartholdyC, ErikssonK, ThomsenAR, PaludanSR. 2006. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol, 80(9):4501–4509.
4.
BrandS, BeigelF, OlszakT, ZitzmannK, EichhorstST, OtteJM, DieboldJ, DiepolderH, AdlerB, AuernhammerCJ, GokeB, DambacherJ. 2005. IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am J Physiol Gastrointest Liver Physiol, 289(5):G960–G968.
5.
CrouchDH, FisherF, La RoccaSA, GodingCR, GillespieDA. 2005. Viral mutations enhance the Max binding properties of the vMyc b-HLH-LZ domain. Nucleic Acids Res, 33(16):5235–5242.
6.
DellgrenC, GadHH, HammingOJ, MelchjorsenJ, HartmannR. 2009. Human interferon-lambda3 is a potent member of the type III interferon family. Genes Immun, 10(2):125–131.
7.
DickensheetsH, SheikhF, ParkO, GaoB, DonnellyRP. 2013. Interferon-lambda (IFN-lambda) induces signal transduction and gene expression in human hepatocytes, but not in lymphocytes or monocytes. J Leukoc Biol, 93(3):377–385.
8.
DiegelmannJ, BeigelF, ZitzmannK, KaulA, GokeB, AuernhammerCJ, BartenschlagerR, DiepolderHM, BrandS. 2010. Comparative analysis of the lambda-interferons IL-28A and IL-29 regarding their transcriptome and their antiviral properties against hepatitis C virus. PLoS One, 5(12):e15200
9.
DonnellyRP, SheikhF, KotenkoSV, DickensheetsH. 2004. The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain. J Leukoc Biol, 76(2):314–321.
10.
DumoutierL, TounsiA, MichielsT, SommereynsC, KotenkoSV, RenauldJC. 2004. Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J Biol Chem, 279(31):32269–32274.
11.
GadHH, HammingOJ, HartmannR. 2010. The structure of human interferon lambda and what it has taught us. J Interferon Cytokine Res, 30(8):565–571.
12.
HassanNF, CampbellDE, DouglasSD. 1986. Purification of human monocytes on gelatin-coated surfaces. J Immunol Methods, 95(2):273–276.
13.
HoWZ, LioyJ, SongL, CutilliJR, PolinRA, DouglasSD. 1992. Infection of cord blood monocyte-derived macrophages with human immunodeficiency virus type 1. J Virol, 66(1):573–579.
HouW, WangX, YeL, ZhouL, YangZQ, RiedelE, HoWZ. 2009. Lambda interferon inhibits human immunodeficiency virus type 1 infection of macrophages. J Virol, 83(8):3834–3842.
16.
JensenS, ThomsenAR. 2012. Sensing of RNA viruses: a review of innate immune receptors involved in recognizing RNA virus invasion. J Virol, 86(6):2900–2910.
17.
KotenkoSV, GallagherG, BaurinVV, Lewis-AntesA, ShenM, ShahNK, LangerJA, SheikhF, DickensheetsH, DonnellyRP. 2003. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol, 4(1):69–77.
18.
KouroumalisA, NibbsRJ, AptelH, WrightKL, KoliosG, WardSG. 2005. The chemokines CXCL9, CXCL10, and CXCL11 differentially stimulate G alpha i-independent signaling and actin responses in human intestinal myofibroblasts. J Immunol, 175(8):5403–5411.
19.
LeeCM, ReddyEP. 1999. The v-myc oncogene. Oncogene, 18(19):2997–3003.
20.
LenschowDJ, GiannakopoulosNV, GunnLJ, JohnstonC, O'GuinAK, SchmidtRE, LevineB, VirginHWt. 2005. Identification of interferon-stimulated gene 15 as an antiviral molecule during Sindbis virus infection in vivo. J Virol, 79(22):13974–13983.
21.
LiM, LiuX, ZhouY, SuSB. 2009. Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses. J Leukoc Biol, 86(1):23–32.
22.
LiY, ZhangT, DouglasSD, LaiJP, XiaoWD, PleasureDE, HoWZ. 2003. Morphine enhances hepatitis C virus (HCV) replicon expression. Am J Pathol, 163(3):1167–1175.
23.
LiuMQ, ZhouDJ, WangX, ZhouW, YeL, LiJL, WangYZ, HoWZ. 2012. IFN-lambda3 inhibits HIV infection of macrophages through the JAK-STAT pathway. PLoS One, 7(4):e35902
24.
MarcelloT, GrakouiA, Barba-SpaethG, MachlinES, KotenkoSV, MacDonaldMR, RiceCM. 2006. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology, 131(6):1887–1898.
25.
NeilSJ, ZangT, BieniaszPD. 2008. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature, 451(7177):425–430.
26.
OkugawaS, MekataT, InadaM, KiharaK, ShikiA, KannabiranK, KonoT, SakaiM, YoshidaT, ItamiT, SudhakaranR. 2013. The SOCS and STAT from JAK/STAT signaling pathway of kuruma shrimp Marsupenaeus japonicus: molecular cloning, characterization and expression analysis. Mol Cell Probes, 27(1):6–14.
27.
OnoguchiK, YoneyamaM, TakemuraA, AkiraS, TaniguchiT, NamikiH, FujitaT. 2007. Viral infections activate types I and III interferon genes through a common mechanism. J Biol Chem, 282(10):7576–7581.
28.
Prokunina-OlssonL, MuchmoreB, TangW, PfeifferRM, ParkH, DickensheetsH, HergottD, Porter-GillP, MumyA, KohaarI, ChenS, BrandN, TarwayM, LiuL, SheikhF, AstemborskiJ, BonkovskyHL, EdlinBR, HowellCD, MorganTR, ThomasDL, RehermannB, DonnellyRP, O'BrienTR. 2013. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet, 45(2):164–171.
SchogginsJW, RiceCM. 2011. Interferon-stimulated genes and their antiviral effector functions. Curr Opin Virol, 1(6):519–525.
34.
SheppardP, KindsvogelW, XuW, HendersonK, SchlutsmeyerS, WhitmoreTE, KuestnerR, GarriguesU, BirksC, RorabackJ, OstranderC, DongD, ShinJ, PresnellS, FoxB, HaldemanB, CooperE, TaftD, GilbertT, GrantFJ, TackettM, KrivanW, McKnightG, CleggC, FosterD, KlucherKM. 2003. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol, 4(1):63–68.
35.
SoroceanuL, AkhavanA, CobbsCS. 2008. Platelet-derived growth factor-alpha receptor activation is required for human cytomegalovirus infection. Nature, 455(7211):391–395.
36.
TaniguchiT, OgasawaraK, TakaokaA, TanakaN. 2001. IRF family of transcription factors as regulators of host defense. Annu Rev Immunol, 19:623–655.
37.
TannerDC, CherryJD, Mayer-ProschelM. 2011. Oligodendrocyte progenitors reversibly exit the cell cycle and give rise to astrocytes in response to interferon-gamma. J Neurosci, 31(16):6235–6246.
38.
ThompsonAJ, LocarniniSA. 2007. Toll-like receptors, RIG-I-like RNA helicases and the antiviral innate immune response. Immunol Cell Biol, 85(6):435–445.
39.
UzeG, MonneronD. 2007. IL-28 and IL-29: newcomers to the interferon family. Biochimie, 89(6–7):729–734.
40.
WangY, YeL, WangX, LiJ, SongL, HoW. 2013. Retinoic acid inducible gene-I (RIG-I) signaling of hepatic stellate cells inhibits hepatitis C virus replication in hepatocytes. Innate Immun, 19(2):193–202.
41.
WilleyRL, SmithDH, LaskyLA, TheodoreTS, EarlPL, MossB, CaponDJ, MartinMA. 1988. In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. J Virol, 62(1):139–147.
42.
WitteK, GruetzG, VolkHD, LoomanAC, AsadullahK, SterryW, SabatR, WolkK. 2009. Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun, 10(8):702–714.
43.
YangK, PuelA, ZhangS, EidenschenkC, KuCL, CasrougeA, PicardC, von BernuthH, SenechalB, PlancoulaineS, Al-HajjarS, Al-GhonaiumA, MarodiL, DavidsonD, SpeertD, RoifmanC, GartyBZ, OzinskyA, BarratFJ, CoffmanRL, MillerRL, LiX, LebonP, Rodriguez-GallegoC, ChapelH, GeissmannF, JouanguyE, CasanovaJL. 2005. Human TLR-7-, -8-, and -9-mediated induction of IFN-alpha/beta and -lambda Is IRAK-4 dependent and redundant for protective immunity to viruses. Immunity, 23(5):465–478.
44.
YuQ, ChenD, KonigR, MarianiR, UnutmazD, LandauNR. 2004. APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J Biol Chem, 279(51):53379–53386.
45.
ZhangL, JilgN, ShaoRX, LinW, FuscoDN, ZhaoH, GotoK, PengLF, ChenWC, ChungRT. 2011. IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway. J Hepatol, 55(2):289–298.
46.
ZhangT, LinRT, LiY, DouglasSD, MaxceyC, HoC, LaiJP, WangYJ, WanQ, HoWZ. 2005. Hepatitis C virus inhibits intracellular interferon alpha expression in human hepatic cell lines. Hepatology, 42(4):819–827.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
